
The Commission temporarily suspended trading in the securities of NewGen BioPharma because of questions regarding the accuracy and adequacy of publicly available information about the company, specifically (i) the identity of its former sole executive officer, director, and majority shareholder; and (ii) possible undisclosed former and current controlling persons. This order was entered pursuant to Section 12(k) of the Securities Exchange Act of 1934 (Exchange Act).

The Commission cautions broker-dealers, shareholders, and prospective purchasers that they should carefully consider the foregoing information along with all other currently available information and any information subsequently issued by the company.

Further, brokers and dealers should be alert to the fact that, pursuant to Rule 15c2-11 under the Exchange Act, at the termination of the trading suspension, no quotation may be entered unless and until they have strictly complied with all of the provisions of the rule. If any broker or dealer has any questions as to whether or not he has complied with the rule, he should not enter any quotation but immediately contact the staff of the Securities and Exchange Commission in Washington, DC at (202) 551-5777. If any broker or dealer is uncertain as to what is required by Rule 15c2-11, he should refrain from entering quotations relating to NewGen BioPharma’s securities until such time as he or she has familiarized himself with the rule and is certain that all of its provisions have been met. If any broker or dealer enters any quotation which is in violation of the rule, the Commission will consider the need for prompt enforcement action.

If any broker-dealer or other person has any information which may relate to this matter, they should contact James L. Buck, Assistant Director, Division of Enforcement at (202) 551-4598 or Edward B. Gerard, Counsel, Division of Enforcement, at (202) 551-8624. The SEC appreciates the assistance of the Financial Industry Regulatory Authority.